Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Court Orders Biota Dispute With GSK To Mediation (Australia)

This article was originally published in PharmAsia News

Executive Summary

An Australian judge ordered Biota Holdings to mediation in its dispute with GlaxoSmithKline over the marketing of the flu drug Relenza (zanamivir). Biota accused GSK in a court suit of not properly promoting the drug Biota developed and GSK licensed. The judge ordered mediation to be completed by May 16, 2008. Biota sued GSK in Australia for as much as $606 million, U.S., noting the drug's sales were overshadowed by Roche Holding's Tamiflu. (Click here for more

You may also be interested in...



Aussie Biotech Biota Closer To Resolution With GSK On Relenza Suit

PERTH, Australia - Biota Holdings' lawsuit with GlaxoSmithKline over antiviral influenza vaccine Relenza (zanamivir) is getting closer to resolution, the Melbourne, Australia-based biotech told PharmAsia News

Austria’s Apeiron To Attack COVID-19 At Its Entry Point

Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark. 
 
 
 

 

Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

UsernamePublicRestriction

Register

SC065880

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel